$VTAE, Vitae Pharmaceuticals to Present at IMMUNO
Post# of 22755
Posted On: 05/09/2016 5:02:35 PM
$VTAE,
Vitae Pharmaceuticals to Present at IMMUNOLOGY 2016
Poster to highlight positive Phase 1 data for RORγ t inhibitor VTP-43742
FORT WASHINGTON, Pa., May 09, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE ), a clinical-stage biotechnology company, today announced that Gerard M. McGeehan, Ph.D., Vice President of Biology, will present a poster titled “Safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-43742, a RORγt inhibitor, in normal healthy volunteers” at IMMUNOLOGY 2016, the American Association of Immunologists’ annual meeting, to be held May 13-17, 2016 in Seattle.
VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment of multiple autoimmune disorders, including psoriasis, through the potent inhibition of IL-17 secretion from Th17 cells and blocking the action of IL-23.
The poster details are as follows:
Title : “Safety, tolerability, pharmacokinetics and pharmacodynamics or VTP-43742, a RORγt inhibitor, in normal healthy volunteers” Session : Late-Breaking Therapeutic Approaches to Autoimmunity Poster : #P2282 Date : Saturday, May 14, 2016 Time : 2:30 to 3:45 p.m. PDT Location : Washington State Convention Center, Exhibit / Poster Hall
For more information on IMMUNOLOGY 2016, please visit http://www.immunology2016.org/ .
About Vitae Pharmaceuticals
Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. Vitae’s lead clinical assets include VTP-43742, an oral RORγt inhibitor currently being studied in patients with moderate to severe psoriasis, and VTP-38543, an LXRβ selective agonist being studied in patients with mild to moderate atopic dermatitis.
For additional information, please visit the company's website at www.vitaepharma.com .
INVESTORS: Vitae Pharmaceuticals, Inc. Richard S. Morris, CPA Chief Financial Officer (215) 461-2000 rmorris@vitaerx.com Westwicke Partners John Woolford (443) 213-0506 john.woolford@westwicke.com MEDIA: 6 Degrees PR Tony Plohoros (908) 591-2839 tplohoros@6degreespr.com
Vitae Pharmaceuticals to Present at IMMUNOLOGY 2016
Poster to highlight positive Phase 1 data for RORγ t inhibitor VTP-43742
FORT WASHINGTON, Pa., May 09, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE ), a clinical-stage biotechnology company, today announced that Gerard M. McGeehan, Ph.D., Vice President of Biology, will present a poster titled “Safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-43742, a RORγt inhibitor, in normal healthy volunteers” at IMMUNOLOGY 2016, the American Association of Immunologists’ annual meeting, to be held May 13-17, 2016 in Seattle.
VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment of multiple autoimmune disorders, including psoriasis, through the potent inhibition of IL-17 secretion from Th17 cells and blocking the action of IL-23.
The poster details are as follows:
Title : “Safety, tolerability, pharmacokinetics and pharmacodynamics or VTP-43742, a RORγt inhibitor, in normal healthy volunteers” Session : Late-Breaking Therapeutic Approaches to Autoimmunity Poster : #P2282 Date : Saturday, May 14, 2016 Time : 2:30 to 3:45 p.m. PDT Location : Washington State Convention Center, Exhibit / Poster Hall
For more information on IMMUNOLOGY 2016, please visit http://www.immunology2016.org/ .
About Vitae Pharmaceuticals
Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. Vitae’s lead clinical assets include VTP-43742, an oral RORγt inhibitor currently being studied in patients with moderate to severe psoriasis, and VTP-38543, an LXRβ selective agonist being studied in patients with mild to moderate atopic dermatitis.
For additional information, please visit the company's website at www.vitaepharma.com .
INVESTORS: Vitae Pharmaceuticals, Inc. Richard S. Morris, CPA Chief Financial Officer (215) 461-2000 rmorris@vitaerx.com Westwicke Partners John Woolford (443) 213-0506 john.woolford@westwicke.com MEDIA: 6 Degrees PR Tony Plohoros (908) 591-2839 tplohoros@6degreespr.com
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼